Erratum

Article Figures & Data

Table 1.

Baseline Demographics and Clinical Characteristics Before or at Start of ¹⁷⁷Lu-PSMA

Characteristic	Data
Patients	133
Age (y)	73 (49–90)
ECOG PS
1	17 (13)
2	49 (37)
3	13 (10)
4	2 (2)
Missing	52 (39)
PSA^* (ng/mL) (n = 130)	286 (1–12,229)
ALP^* (U/L) (n = 112)	146 (23–973)
Extent of metastatic disease^†
Bone metastases with lymph node metastases	63 (47)
Bone metastases without lymph node metastases	33 (25)
Visceral metastases	36 (27)
Prior therapies for mCRPC, n (%)
≥4 Life-prolonging therapies^‡	76 (57)
²²³Ra	133 (100)
Number of ²²³Ra injections
1–4	35 (26)
5–6	98 (74)
Abiraterone	95 (71)
Enzalutamide	92 (69)
Abiraterone and enzalutamide	71 (53)
Chemotherapy lines^§
0	31 (23)
1	67 (50)
≥2	35 (26)
Docetaxel	99 (74)
Cycles^ǁ
1 − 4	27 (24)
≥5	59 (53)
Missing/unknown	26 (23)
Cabazitaxel	30 (23)
Cycles^¶
1 − 4 cycles	7 (21)
≥5 cycles	14 (42)
Missing/unknown	12 (36)

↵* In case of multiple measures, value nearest to ¹⁷⁷Lu-PSMA start was chosen.
↵^† Prebaseline period, patient may have multiple metastatic diseases.
↵^‡ Docetaxel, cabazitaxel, abiraterone, enzalutamide, ²²³Ra.
↵^§ Chemotherapies with same start date ± 15 d were counted as 1 line.
↵^ǁ n = 112; percentages were based on number of docetaxel therapies (i.e., patients who received 2 lines of docetaxel were counted twice).
↵^¶ n = 33; percentages were based on number of cabazitaxel therapies (i.e., patients who received 2 lines of cabazitaxel were counted twice).
ECOG PS = Eastern Cooperative Oncology Group performance status. Qualitative data are number and percentage; continuous data are median and range.